The components of the complex are also druggable targets; PARP inhibitors are already being used as a treatment for women with ovarian or fallopian tube cancers [14, 51, 86] and may have a benefit in P53 null and/or ARID1a null cancers which are glucocorticoid resistant. This evidence concerns the gene TP53 and fallopian tube cancer.